Cadinha & Co’s AbbVie ABBV Stock Holding History

Cadinha & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.79M	Sell	11,083 -227	-2%	-$48.8K	0.41%	37
2026 Q1	$2.46M	Sell	11,310 -135	-1%	-$29.9K	0.46%	32
2025 Q4	$2.62M	Hold	11,445	–	–	0.4%	30
2025 Q3	$2.65M	Hold	11,445	–	–	0.36%	35
2025 Q2	$2.12M	Buy	11,445 +11	+0.1%	+$2.04K	0.35%	35
2025 Q1	$2.4M	Buy	11,434 +9	+0.1%	+$1.75K	0.51%	29
2024 Q4	$2.03M	Sell	11,425 -161	-1%	-$29.6K	0.34%	34
2024 Q3	$2.29M	Hold	11,586	–	–	0.39%	31
2024 Q2	$1.99M	Buy	11,586 +23	+0.2%	+$3.81K	0.37%	34
2024 Q1	$2.11M	Sell	11,563 -400	-3%	-$68.9K	0.36%	35
2023 Q4	$1.85M	Buy	11,963 +50	+0.4%	+$7.29K	0.3%	38
2023 Q3	$1.78M	Sell	11,913 -50	-0.4%	-$7.34K	0.39%	35
2023 Q2	$1.61M	Buy	11,963 +138	+1%	+$20.2K	0.29%	36
2023 Q1	$1.88M	Buy	11,825 +200	+2%	+$30.6K	0.52%	30
2022 Q4	$1.88M	Hold	11,625	–	–	0.42%	29
2022 Q3	$1.56M	Hold	11,625	–	–	0.53%	23
2022 Q2	$1.78M	Hold	11,625	–	–	0.4%	28
2022 Q1	$1.89M	Hold	11,625	–	–	0.27%	39
2021 Q4	$1.57M	Hold	11,625	–	–	0.21%	45
2021 Q3	$1.25M	Sell	11,625 -3,000	-21%	-$343K	0.18%	55
2021 Q2	$1.65M	Sell	14,625 -5,100	-26%	-$574K	0.22%	52
2021 Q1	$2.13M	Hold	19,725	–	–	0.31%	48
2020 Q4	$2.11M	Hold	19,725	–	–	0.29%	44
2020 Q3	$1.73M	Hold	19,725	–	–	0.3%	41
2020 Q2	$1.94M	Hold	19,725	–	–	0.33%	41
2020 Q1	$1.5M	Hold	19,725	–	–	0.4%	33
2019 Q4	$1.75M	Hold	19,725	–	–	0.25%	58
2019 Q3	$1.49M	Buy	19,725 +83	+0.4%	+$5.69K	0.24%	53
2019 Q2	$1.43M	Hold	19,642	–	–	0.26%	54
2019 Q1	$1.58M	Sell	19,642 -369	-2%	-$30.2K	0.31%	50
2018 Q4	$1.84M	Sell	20,011 -2,000	-9%	-$176K	0.46%	36
2018 Q3	$2.08M	Sell	22,011 -652	-3%	-$61.8K	0.33%	47
2018 Q2	$2.1M	Buy	22,663 +170	+0.8%	+$16.6K	0.38%	40
2018 Q1	$2.13M	Sell	22,493 -1,100	-5%	-$121K	0.43%	39
2017 Q4	$2.28M	Sell	23,593 -310	-1%	-$29.2K	0.32%	50
2017 Q3	$2.12M	Hold	23,903	–	–	0.36%	43
2017 Q2	$1.73M	Buy	23,903 +239	+1%	+$16.1K	0.3%	45
2017 Q1	$1.54M	Buy	23,664 +1,800	+8%	+$113K	0.31%	44
2016 Q4	$1.37M	Sell	21,864 -1,168	-5%	-$71.3K	0.24%	42
2016 Q3	$1.45M	Hold	23,032	–	–	0.3%	46
2016 Q2	$1.43M	Hold	23,032	–	–	0.31%	47
2016 Q1	$1.32M	Hold	23,032	–	–	0.34%	42
2015 Q4	$1.36M	Hold	23,032	–	–	0.32%	44
2015 Q3	$1.25M	Sell	23,032 -100	-0.4%	-$6.51K	0.3%	43
2015 Q2	$1.55M	Buy	23,132 +3,055	+15%	+$199K	0.31%	44
2015 Q1	$1.18M	Sell	20,077 -500	-2%	-$30.2K	0.23%	51
2014 Q4	$1.35M	Sell	20,577 -512	-2%	-$32.3K	0.23%	50
2014 Q3	$1.22M	Hold	21,089	–	–	0.22%	49
2014 Q2	$1.19M	Sell	21,089 -200	-0.9%	-$10.5K	0.2%	50
2014 Q1	$1.09M	Sell	21,289 -540	-2%	-$27.3K	0.2%	49
2013 Q4	$1.15M	Sell	21,829 -300	-1%	-$14.7K	0.21%	49
2013 Q3	$990K	Buy	22,129 +200	+0.9%	+$8.87K	0.2%	47
2013 Q2	$907K	Buy	+21,929	New	+$959K	0.21%	39

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cadinha & Co's ABBV Position: Q2 2026 in Review

Cadinha & Co reduced its AbbVie (ABBV) stake by 2% in Q2 2026, selling an estimated $48.8K and leaving 11,083 shares worth $2.79M. The position accounts for 0.41% of the portfolio, ranked #37.

Cadinha & Co first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cadinha & Co held 11,083 shares of AbbVie worth $2.79M as of Q2 2026.
Cadinha & Co sold 227 AbbVie shares in Q2 2026, an estimated $48.8K.
AbbVie made up 0.41% of Cadinha & Co's portfolio in Q2 2026, its #37 holding.
Cadinha & Co first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cadinha & Co's 13F filing for Q2 2026, filed 28 Jul 2026.